查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049542

神經生物標記市場規模、佔有率、趨勢和預測：按類型、應用、最終用途和地區分類，2026-2034年

Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年全球神經生物標記市場規模為110億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以9.96%的複合年成長率成長，到2034年達到266億美元。北美地區預計在2025年將佔據神經生物標記市場41.6%以上的佔有率，這主要得益於神經系統疾病發病率的上升、完善的醫療保健體係以及研發投入的加速。此外，生物標記在早期診斷中的應用日益廣泛、臨床試驗的擴展以及生物技術公司與研究機構之間為開發神經系統疾病創新治療方法而加強的合作，也將進一步推動市場成長。

中風、運動神經元疾病（MND）、阿茲海默症（AD）、巴金森氏症（PD）和亨丁頓舞蹈症（HD）等神經系統疾病發生率的上升，使得加速藥物研發的需求日益成長。生物標記是市場成長的關鍵促進因素，因為它們有助於評估新藥和治療策略的有效性。微創手術和個人化醫療的日益普及是市場成長的另一個主要驅動力。此外，多種神經系統疾病具有通用特徵，因此需要多種生物標記來區分特定疾病及其亞型。質譜和成像技術的進步使得大腦中多種生化標記和結構變化的評估速度更快。結合數位生物標記的引入和臨床試驗的增加，這些因素預計將在未來幾年推動市場成長。

美國憑藉其先進的醫療保健基礎設施和對醫學研究的大力投入，在全球神經系統疾病生物標記市場佔據主導地位。包括阿茲海默症和帕金森氏症在內的神經系統疾病的高發生率，推動了對創新診斷工具的需求。例如，產業報告顯示，目前美國約有100萬人患有帕金森氏症，預計到2030年將增加至120萬人。此外，美國在生物技術和製藥行業的巨額投資，加速了神經系統生物標記的開發和商業化。監管支援和遍布最尖端科技醫院檢查室也進一步促進了市場成長。美國在推動個人化醫療、改善疾病早期檢測和管理方面繼續發揮著至關重要的作用。

神經生物標記市場的發展趨勢：

神經系統疾病發生率增加

正如世界衛生組織2024年報告所述，神經系統疾病是健康損害和殘疾的主要原因。報告指出，1990年，神經系統疾病導致的殘疾、健康損害或過早死亡所造成的失能調整後存活年（DALYs）總體負擔增加了18%。這些成長均歸因於阿茲海默症、帕金森氏症和多發性硬化症（MS）盛行率的上升。此外，全球人口老化也推動了全球神經系統生物標記市場的成長，因為這增加了對利用生物標記進行疾病檢測和監測的診斷工具的需求。

生物技術和基因組研究的進展

基因組學、蛋白質組學和分子生物學的進步極大地促進了神經系統疾病更準確、更精確的生物標記的開發。事實上，這些進步不僅提高了診斷的準確性，也有助於疾病的早期發現和治療效果的監測。根據世界衛生組織2023年2月發表的一篇報導，全球每年約有500萬人被新診斷為癲癇，這推動了對精準診斷技術的需求。此外，隨著老年阿茲海默症症患者數量的增加，由於早期檢測、監測和標靶治療的持續發展，預計市場將進一步擴大。

對個人化醫療的需求日益成長

個人化醫療根據患者的基因組成和各種疾病的生物標記，客製化和開發干預措施和治療方法以滿足個人需求，其發展速度正在迅速超越其他醫藥領域。神經生物標記是推動此類個人化療法發展的關鍵要素，能夠有效支持疾病特異性分子特徵的識別和多種治療方法的改進。因此，個人化醫療有望推動全球神經生物標記市場的成長。根據阿茲海默症協會統計，目前全球有5,500萬人患有失智症，預計到2030年這數字將增加至7,800萬，到2050年將達到約1.39億。這些疾病病例數量的顯著成長凸顯了對更精準的標靶治療和診斷工具的迫切需求，進一步增加了神經生物標記在神經系統疾病管理和治療中的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球神經生物標記市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 基因生物標記
  • 蛋白質體學生物標記
  • 代謝組學生物標記
  • 影像生物標記
  • 其他

第7章 市場區隔：依應用領域分類

  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 泛自閉症障礙
  • 其他

第8章 市場區隔：依最終用途分類

  • 醫院實驗室
  • 臨床診斷中心
  • 研究機構
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Acumen Pharmaceuticals Inc.
    • Athena Diagnostics（Quest Diagnostics）
    • Banyan Biomarkers Inc.
    • Bio-Rad Laboratories Inc.
    • Immunarray Pvt. Ltd.
    • Myriad Rbm Inc.（Myriad Genetics Inc.）
    • Proteome Sciences Plc
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A3181

The global neurological biomarkers market size was valued at USD 11.0 Billion in 2025 . Looking forward, IMARC Group estimates the market to reach USD 26.6 Billion by 2034, exhibiting a CAGR of 9 .96% during 2026-2034. North America currently dominates the neurological biomarkers market share, of over 41.6% in 2025, driven by escalating incidents of neurological conditions, robust healthcare systems, and accelerated high research investments. The growth of the market is further fueled by an increase in biomarkers adoption for early diagnosis, expanded clinical trials, and growing collaborations between biotech companies and research organizations to develop innovative neurological treatments.

The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

The United States holds a prominent position in the global neurological biomarkers market share, driven by its advanced healthcare infrastructure and strong focus on medical research. With a high prevalence of neurological disorders, including Alzheimer's and Parkinson's disease, there is a growing demand for innovative diagnostic tools. For instance, as per industry reports, around 1 million U.S. population is affected with Parkinson's disease, and this count is anticipated to elevate to 1.2 million by the year 2030. Furthermore, the U.S. benefits from significant investments in biotechnology and pharmaceutical industries, fostering the development and commercialization of neurological biomarkers. Additionally, regulatory support and a large base of hospital laboratories equipped with cutting-edge technologies further enhance market growth. The U.S. remains a key player in advancing personalized medicine and improving early disease detection and management.

NEUROLOGICAL BIOMARKERS MARKET TRENDS :

Rising Incidence of Neurological Disorders

As highlighted by a report from WHO in 2024, neurological disorders have become the number one cause of ill health and disability. According to reports, DALYs of overall burden due to disability, ill health, or early death as a result of neurological disorders in 1990 has been stated to be the 18-percentage increase in general. These all are attributed with the growth incidence of Alzheimer, Parkinson's as well as multiple sclerosis (MS). In addition to this, the aging population in the world increases the demand for diagnostic tools with biomarkers in the detection and monitoring of diseases, thereby propelling the neurological biomarkers market growth globally.

Advancements in Biotechnology and Genomic Research

Advances in genomics, proteomics, and molecular biology have contributed much towards developing far more accurate and precise biomarkers for neurologic disorders. Actually, these advances have enhanced diagnostic precision as well as facilitated early detection of diseases and better monitoring of responses to treatment. According to an article from the WHO released in February 2023, almost 5 million people worldwide are newly diagnosed each year with epilepsy, with the call for precise diagnostic techniques. In addition, the elderly population's increase in Alzheimer's disease is predicted to further expand the market due to the continuing growth in early detection, monitoring, and directed treatments.

Increasing Demand for Personalized Medicine

Personalized medicine is rapidly surpassing other pharmaceutical components, in which interventions and treatment methods are customized and formulated as per the individual needs of a patient, based on their genetic makeup and biomarkers of various disease. Neurological biomarkers are the crucial components that significantly facilitate this kind of personalized treatment, thereby actively supporting the identification of disease-specific molecular signatures and refinement of varied therapeutic methods. As a result, personalized medicine is anticipated to bolster the expansion of the neurological biomarkers market forecast globally. According to the Alzheimer's Association, currently 55 million people worldwide are suffering from dementia; this number is suspected to elevate to 78 million by the year 2030 and to almost 139 million by 2050. The notable increase in cases of such conditions highlights the indispensable requirement for more precise targeted therapies as well as diagnostic tools, further escalating the need for neurological biomarkers in both the management and treatment of neurological disorders.

NEUROLOGICAL BIOMARKERS INDUSTRY SEGMENTATION:

Analysis by Type:

  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers
  • Imaging Biomarkers
  • Others

Based on the neurological biomarkers market forecast, proteomic biomarkers lead the market with around 31.2% of market share in 2025, chiefly because of their excellent capability to locate disease-associated proteins and their role in comprehending complicated neurological conditions. Such biomarkers are critical in identifying particular protein alterations in the brain that can play the role of early indicators for neurodegenerative disorders, mainly including Parkinson's and Alzheimer's disease. Besides, the growing emphasis on personalized therapies as well as precision medicine has significantly bolstered the requirement for proteomic biomarkers, mainly because they foster targeted treatment methodologies. In addition, active innovations in protein analysis methods and mass spectrometry have facilitated more dependable and precise biomarker discovery. Furthermore, the amplifying acknowledgement of proteomic biomarkers' potential to substantially improve diagnostic accuracy, combined with their feasibility in disease assessment and prognosis, guarantees that this type continues to dominate the market. The incorporation of proteomic biomarkers with several other diagnostic technologies further fortifies their position as a crucial driver propelling the neurological biomarkers market demand.

Analysis by Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others

Alzheimer's disease holds the largest market share by application in the global neurological biomarkers market, mainly influenced by its accelerated prevalence and the urgent demand for efficient management and early diagnosis. As the most prevalent type of dementia, Alzheimer's exhibits notable healthcare challenges worldwide, with a rapid increase in geriatric population fueling its escalating incidence. Early detection of Alzheimer's disease enables for timely interventions, likely reducing disease progression and enhancing patient outcomes. Moreover, biomarkers, including tau proteins and amyloid-beta, coupled with rising blood-based markers, are crucial in diagnosing Alzheimer's at its early phases. In addition, the requirement for non-invasive, precise biomarkers for Alzheimer's diagnosis has resulted in a constant innovation and research initiatives. Furthermore, biomarkers are requisite in assessing treatment effectiveness, aiding in tailoring personalized therapeutic tactics. Given the profound economic as well as social impacts of Alzheimer's disease, its management via biomarkers remains a leading priority in neurological healthcare and research, straightening its leading market share and contributing to a positive neurological biomarkers market outlook.

Analysis by End Use:

  • Hospital Laboratories
  • Clinical Diagnostic Centers
  • Research Organizations
  • Others

Hospital laboratories represent the largest segment by end use in the global neurological biomarkers market, as they play a central role in the diagnosis and monitoring of neurological conditions. These laboratories are equipped with advanced diagnostic technologies, enabling the efficient testing and analysis of neurological biomarkers, which are essential for disease detection and prognosis. With the rising incidence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, hospital laboratories are increasingly relied upon for early diagnosis and treatment decision-making. Their ability to provide accurate, timely results supports improved patient outcomes and aids in the development of personalized treatment plans. Furthermore, hospital laboratories benefit from regulatory approvals and the integration of new biomarker assays, which enhance their diagnostic capabilities. Moreover, as healthcare systems evolve, hospital laboratories remain at the forefront of leveraging neurological biomarkers to address the growing burden of neurological diseases, thus driving their significant share in the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 41.6%, driven by magnifying cases prevalence of neurological conditions, well-established healthcare infrastructure, and innovative research abilities. For instance, as per industry reports, by 2030, in Canada, around 1 million people are expected to be living with dementia, an umbrella term for memory-related neurological disorder encompassing Alzheimer's, with projections exceeding 1.7 million by 2050. Moreover, the region notably profits from heavy investments in pharmaceuticals and biotechnology sectors, facilitating advancements in diagnostic technologies as well as biomarker discovery. In additionally, North America's amplifying need for early detection and customized treatment options for neurological conditions, mainly encompassing Parkinson's and Alzheimer's, further boosts market growth. The beneficial regulatory ecosystem and presence of leading players in Canada and the U.S. also fuel the region's domination in the neurological biomarkers industry.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

In 2025, United States accounted for the 91.00% of the market share in North America. The neurological disorders market in the United States is being heavily driven by an increase in the prevalence of neurological disorders. Stroke has been estimated to be the third cause of death in the country, and Parkinson's disease has been documented to have around 1 million affected individuals, as per reports. The increasing cases for other neurological diseases, such as Alzheimer's and epilepsy, also look at the rising demand for accurate diagnostics and biomarkers. All of these requirements-the need for early detection, the use of individualized treatment plans, and ongoing monitoring of the disease process-propel the implementation of neurological biomarkers. Since the field of genomics, proteomics, and molecular biology is continuously progressing, new and more specific biomarkers are found, thus better diagnostic accuracy and treatment monitoring. Increasing number of the geriatric population along with an ever-growing awareness toward neurological conditions, in turn, are anticipated to continue propelling demand for biomarkers in the United States-ensuring it a critical role in patient outcome enhancement and disease management.

EUROPE NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

The neurological conditions are increasingly developing in Europe and are the greatest driver for this market. Alzheimer's Society recently reported that around 850,000 people living in the UK were suffering from dementia in 2019. This is how the incidence of neurological disorders increases in the region. This means, on average, 1 of every 14 individuals above 65 years suffer from dementia- a statistic underlining the growing need for highly advanced diagnostic tools. With aging populations on the rise, more neurological biomarkers that can help to detect diseases earlier, diagnose it, and then monitor it including Alzheimer's disease, Parkinson's disease, or multiple sclerosis is expected to continue rising. Advances in molecular biology, genomics, and proteomics are enabling the discovery of more specific and reliable biomarkers, further fueling the adoption of these diagnostic tools. In the coming years, the increasing burden of neurological diseases in Europe is expected to drive the market for neurological biomarkers.

ASIA PACIFIC NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

The Asia Pacific neurological biomarkers market is booming because of the increased incidence and prevalence of neurological disorders such as Parkinson's Disease (PD). The NIH estimated that from 1990 to 2021, the incidence of PD in Asia increased by 198.01%, while its prevalence rose by 284.35%, mortality by 111.27%, and disability-adjusted life years (DALY) by 144.45%. These disturbing statistics draw attention to an ever-increasing burden of neurological conditions in the region. Additionally, the statistics point to a significant growing gender gap where males constantly demonstrate a more significant burden than females. Due to the rise in the number of aging individuals in Asia Pacific, the requirements for early diagnosis and monitoring of neurological diseases will continue to increase over time. This trend drives the need for advanced biomarkers to aid in the detection and tracking of conditions like PD, Alzheimer's, and other neurodegenerative diseases, further propelling the market for neurological biomarkers in the region.

LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

The Latin America neurological biomarkers market is expected to undergo a significant boost with the surging prevalence of dementia in this region. Within the last ten years, many Latin American nations have reported an increase in prevalence rates of dementia from 6.2% to 12.1% among the older population aged 65 and more. The NIH estimates that dementia will affect the region most within the decade ahead, with data for the year 2022. The burden of healthcare is expected to increase manifolds with dementia patient count increasing close to four fold by 2050. Such an alarming rise of dementia further brings forth the demand for advanced diagnostic tools that include neurological biomarkers in the detection and monitoring of such conditions. The growth of the aging population and the increasing prevalence of neurodegenerative diseases have fueled the growth of the neurological biomarkers market in Latin America, as the need for efficient biomarkers for early diagnosis and personalized treatment continues to grow.

MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

The neurological biomarkers market in the Middle East and Africa is experiencing an increase due to the increasing dementia burden, mainly in low and middle-income countries. Dementia prevalence in this region ranges between 2.3% and 20.0%, and the incidence rates are at 13.3 per 1000 person-years, as NIH data shows for 2023. As the continent of Africa accelerates its population's urbanization and aging population, the statistics of dementia increases, leading to higher mortality counts, especially for regions that transform rapidly. There is a trend of increased occurrence of dementia patients, which demands more healthcare systems worldwide, thus presenting a growing interest in effective solutions for diagnosis in the form of neurological biomarkers. These biomarkers play a significant role in the early detection and follow-up of neurodegenerative diseases like dementia. This is, therefore, fueling the need for advanced diagnostic tools in the Middle East and Africa. Other factors driving the growth of this market in this region include rising healthcare burden and an aging population.

COMPETITIVE LANDSCAPE:

The market is extensively competitive, exhibiting a fusion of diagnostic solution providers, established pharmaceutical firms, and biotechnology companies. Leading players are currently emphasizing on tactical acquisition, partnerships, and research investments to proliferate their product portfolios. Moreover, industry giants, including Abbott Laboratories and Siemens Healthineers, utilize leading-edge technologies such as neuroimaging, genomic sequencing, and proteomics to offer upgraded products. For instance, in October 2024, Siemens Healthineers announced becoming the fisrt company to recieve Health Canada Licensing for its blood-based biomarker Neurofilament Light Chain (NfL), which is developed particularly for diagnosing and managing Multiple Sclerosis, a severe neurological condition. The company announced the commercial availability of this biomarker in Canada market. In addition, smaller, innovative firms are also establishing themselves gradually with customized medicine solutions and specialized biomarker assays. Furthermore, competitive tactics gravitate on designing novel biomarkers for various neurological disorders, including Parkinson's and Alzheimer's diseases, improving diagnostic precision, and enhancing patient outcomes.

The report provides a comprehensive analysis of the competitive landscape in the neurological biomarkers market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • Athena Diagnostics (Quest Diagnostics)
  • Banyan Biomarkers Inc.
  • Bio-Rad Laboratories Inc.
  • Immunarray Pvt. Ltd.
  • Myriad Rbm Inc. (Myriad Genetics Inc.)
  • Proteome Sciences Plc
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the neurological biomarkers market?
  • 2.What is the expected growth rate of the global Neurological Biomarkers market during 2026-2034?
  • 3.What are the trends in the neurology market?
  • 4.Which segment accounted for the largest neurological biomarkers market share?
  • 5.Which is the fastest growing region in neurological biomarkers market?
  • 6.Which are the top companies to hold the market share in neurological biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurological Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Genomic Biomarkers
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Proteomic Biomarkers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Metabolomic Biomarkers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Imaging Biomarkers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Alzheimer's Disease
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parkinson's Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Multiple Sclerosis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Autism Spectrum Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospital Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinical Diagnostic Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Organizations
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Acumen Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Athena Diagnostics (Quest Diagnostics)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Banyan Biomarkers Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Immunarray Pvt. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Proteome Sciences Plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Thermo Fisher Scientific Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Neurological Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Neurological Biomarkers Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Neurological Biomarkers Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Neurological Biomarkers Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Neurological Biomarkers Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Neurological Biomarkers Market: Breakup by End Use (in %), 2025
  • Figure 7: Global: Neurological Biomarkers Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Neurological Biomarkers (Genomic Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Neurological Biomarkers (Genomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Neurological Biomarkers (Proteomic Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Neurological Biomarkers (Proteomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Neurological Biomarkers (Imaging Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Neurological Biomarkers (Imaging Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Neurological Biomarkers (Alzheimer's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Neurological Biomarkers (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Neurological Biomarkers (Parkinson's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Neurological Biomarkers (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Neurological Biomarkers (Multiple Sclerosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Neurological Biomarkers (Multiple Sclerosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Neurological Biomarkers (Hospital Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Neurological Biomarkers (Hospital Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Neurological Biomarkers (Research Organizations) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Neurological Biomarkers (Research Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: North America: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: North America: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: United States: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: United States: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Canada: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Canada: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Asia-Pacific: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Asia-Pacific: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: China: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: China: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Japan: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Japan: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: India: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: India: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: South Korea: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: South Korea: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Australia: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Australia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Indonesia: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Indonesia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Europe: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Europe: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Germany: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Germany: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: France: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: France: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: United Kingdom: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: United Kingdom: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Italy: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Italy: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Spain: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Spain: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Russia: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Russia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Latin America: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Latin America: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Brazil: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Brazil: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Mexico: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Mexico: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Middle East and Africa: Neurological Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Middle East and Africa: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Middle East and Africa: Neurological Biomarkers Market: Breakup by Country (in %), 2025
  • Figure 85: Global: Neurological Biomarkers Industry: SWOT Analysis
  • Figure 86: Global: Neurological Biomarkers Industry: Value Chain Analysis
  • Figure 87: Global: Neurological Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurological Biomarkers Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Neurological Biomarkers Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Neurological Biomarkers Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Neurological Biomarkers Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 5: Global: Neurological Biomarkers Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Neurological Biomarkers Market: Competitive Structure
  • Table 7: Global: Neurological Biomarkers Market: Key Players